Join Drs Tania Jain and Raajit Rampal as they discuss TP53, post-MPN AML, and high-risk MPNs in the context of myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999596. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview

Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/

Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/36632576/

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis https://meetings.asco.org/abstracts-presentations/231688

Next Generation Sequencing in MPNs. Lessons From the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses https://pubmed.ncbi.nlm.nih.gov/32781570/

The MDM2 Antagonist Idasanutlin in Patients With Polycythemia Vera: Results From a Single-Arm Phase 2 Study https://ashpublications.org/bloodadvances/article/6/4/1162/483223/The-MDM2-antagonist-idasanutlin-in-patients-with

Venetoclax With Azacitidine or Decitabine in Blast-Phase Myeloproliferative Neoplasm: A Multicenter Series of 32 Consecutive Cases https://pubmed.ncbi.nlm.nih.gov/33844862/

Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation Versus Nontransplantation Therapies in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/33798769/

Genomic Analysis of Primary and Secondary Myelofibrosis Redefines the Prognostic Impact of ASXL1 Mutations: a FIM Study https://pubmed.ncbi.nlm.nih.gov/33666653/

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/27959731/

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Accelerated and Blast-phase Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/30563881/

Efficacy and Safety of Combination Therapies vs Monotherapy of Hypomethylating Agents in Accelerated or Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: a Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36644935/

Genomic and Functional Analysis of Leukemic Transformation of Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/25516983/

BMP2/SMAD Pathway Activation in JAK2/p53-Mutant Megakaryocyte/Erythroid Progenitors Promotes Leukemic Transformation https://pubmed.ncbi.nlm.nih.gov/35421216/

Single-Cell Multi-omics Identifies Chronic Inflammation as a Driver of TP53-Mutant Leukemic Evolution https://pubmed.ncbi.nlm.nih.gov/37666991/